Welcome to our dedicated page for Sellas Life Sciences Group news (Ticker: SLS), a resource for investors and traders seeking the latest updates and insights on Sellas Life Sciences Group stock.
SELLAS Life Sciences Group, Inc. develops novel cancer therapeutics as a late-stage clinical biopharmaceutical company. News about SLS centers on its acute myeloid leukemia programs, including galinpepimut-S (GPS), a WT1-directed peptide immunotherapy evaluated in the REGAL Phase 3 trial, and SLS009 (tambiciclib), a selective CDK9 inhibitor studied in AML settings.
Recurring updates include clinical and preclinical data presentations, trial progress, regulatory and corporate updates, financial results, cash-position disclosures, warrant exercises, and other capital-structure developments tied to funding its oncology pipeline.
SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) reported its Q1 2020 financial results, emphasizing its commitment to ongoing clinical trials despite the COVID-19 pandemic. The company focuses on developing cancer immunotherapies with key progress in its galinpepimut-S (GPS) and nelipepimut-S (NPS) programs. As of March 31, 2020, cash and cash equivalents stood at $6.7 million. The net loss for the quarter was $4.2 million, with a loss per share of $0.66. Positive follow-up data for GPS indicated a median overall survival of 21 months for AML patients, compared to 5.4 months for standard care.